Cover Image
市場調查報告書

製藥業的聯盟、許可證、投資、M&A交易與趨勢:2014年

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2017 in Pharmaceuticals

出版商 GlobalData 商品編碼 331738
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
製藥業的聯盟、許可證、投資、M&A交易與趨勢:2014年 Partnerships, Licensing, Investments and M&A Deals and Trends for April 2017 in Pharmaceuticals
出版日期: 2017年06月05日 內容資訊: 英文 74 Pages
簡介

本報告以全球製藥業的聯盟、許可證、M&A、資金籌措相關主要資料與趨勢分析為焦點,提供過去5年的交易數量與交易額 (各交易類型、治療領域、地區) 相關驗證,製藥業的投資顧問公司相關最新資訊等系統性資訊。

第1章 目錄

第2章 全球製藥、醫療市場:交易摘要

  • 交易分析
  • 各類型,交易數量
  • 各類型,交易額
  • 主要交易
  • 主要交易摘要

第3章 全球製藥、醫療市場:主要交易契約者

第4章 全球製藥、醫療市場:交易摘要 (各類型)

  • M&A
  • 股票上市交易
  • 債券發行交易
  • 聯盟交易
  • 授權合約
  • 私募股權發行交易
  • 創業投資交易

第5章 全球製藥、醫療市場:交易摘要 (各市場)

  • 腫瘤
  • 中樞神經系統
  • 感染疾病
  • 免疫系
  • 心血管系統
  • 代謝障礙
  • 消化道

第6章 製藥、醫療市場:交易摘要 (各地區)

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 全球製藥、醫療市場:主要投資顧問公司

  • M&A
  • 股票上市

第8章 其他資訊

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2017 10
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2017 11
    • 2.2.1 Bain Capital Private Equity and Cinven Partners to Acquire Stada Arzneimittel for up to USD5.61 Billion 11
    • 2.2.2 Fresenius to Acquire Akorn 12
    • 2.2.3 Lonza Raise USD2.24 Billion in Rights Offering of Shares 12
    • 2.2.4 PeptiDream Enters into Agreement with Janssen Pharma 13
    • 2.2.5 Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 13
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2017 14
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2017 14

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 16

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2017 16
    • 3.1.1 Top M&A Deals in April 2017 17
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2016- April 2017 18
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2017 19
    • 3.2.1 Top Equity Offering Deals in April 2017 20
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2016- April 2017 21
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2017 22
    • 3.3.1 Top PE/VC Deals in April 2017 23
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2017 24
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2017 25
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016-April 2017 26
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-April 2017 27
  • 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2017 28
  • 3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2016- April 2017 29
  • 3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2017 30
    • 3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2017 31
  • 3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2016- April 2017 31
  • 3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2016- April 2017 32
  • 3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2016- April 2017 33
  • 3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2016- April 2017 34

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2017 36

  • 4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2017 36
  • 4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2017 37
  • 4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2016- April 2017 38
  • 4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2016- April 2017 39
  • 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2016- April 2017 40
  • 4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2016- April 2017 42
    • 4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2017 43
    • 4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2017 43
    • 4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, April 2017 44

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 45

  • 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2017 45
    • 5.1.1 Oncology - Deals of the Month 46
  • 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2017 47
    • 5.2.1 Central Nervous System - Deals of the Month 48
  • 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2017 50
    • 5.3.1 Infectious Diseases - Deals of the Month 51
  • 5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2017 52
    • 5.4.1 Cardiovascular - Deal of the Month 53
  • 5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2017 54
    • 5.5.1 Immunology - Deals of the Month 55
  • 5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, April 2017 56
    • 5.6.1 Gastrointestinal - Deal of the Month 57
  • 5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, April 2017 58
    • 5.7.1 Metabolic Disorders - Deal of the Month 59

6 Deal Summary by Geography 60

  • 6.1 Pharmaceuticals & Healthcare, North America Deals, April 2017 60
    • 6.1.1 North America - Deals of the Month 61
  • 6.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2017 63
    • 6.2.1 Europe - Deals of the Month 64
  • 6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2017 66
    • 6.3.1 Asia-Pacific - Deals of the Month 67
  • 6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2017 68
    • 6.4.1 Rest of the World - Deals of the Month 69

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 70

  • 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2016- April 2017 70
  • 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2016- April 2017 71

8 Further Information 72

  • 8.1 Methodology 72
  • 8.2 About GlobalData 73
  • 8.3 Contact Us 73
  • 8.4 Disclosure information 74
  • 8.5 Disclaimer 74

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 11
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2017 11
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2017 15
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 17
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2017 17
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2016- April 2017 18
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 20
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2017 20
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 21
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 23
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2017 23
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2016- April 2017 24
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2017 26
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2016- April 2017 27
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2016- April 2017 27
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2016- April 2017 28
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016- April 2017 29
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016- April 2017 30
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2017 31
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2016- April 2017 32
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2016- April 2017 33
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2016- April 2017 35
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 36
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2016- April 2017 37
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016- April 2017 38
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2017 39
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2016- April 2017 41
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2017 43
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2017 43
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2017 43
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2017 44
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 46
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 48
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 51
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 53
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 55
  • Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 57
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 59
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 61
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 64
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 67
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 68
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2016- April 2017 70
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2016- April 2017 71

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2016- April 2017 10
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), April 2017 14
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2017 14
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2016- April 2017 16
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2016- April 2017 18
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2016- April 2017 19
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016- April 2017 21
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2016- April 2017 22
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2016- April 2017 24
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), April 2017 25
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2017 25
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2016- April 2017 26
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2016- April 2017 28
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016- April 2017 29
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016- April 2017 30
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2016- April 2017 31
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2016- April 2017 32
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2016- April 2017 33
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2016- April 2017 34
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2016- April 2017 36
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016- April 2017 37
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2016- April 2017 38
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2016- April 2017 39
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, November 2016- April 2017 40
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2016- April 2017 40
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2017 42
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2016- April 2017 45
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2016- April 2017 47
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2016- April 2017 50
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2016- April 2017 52
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2016- April 2017 54
  • Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 56
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2016- April 2017 58
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2016- April 2017 60
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2016- April 2017 63
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2016- April 2017 66
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2016- April 2017 68
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2016- April 2017 70
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2016- April 2017 71
Back to Top